Oncternal Therapeutics

OverviewSuggest Edit

Oncternal Therapeutics is a clinical-stage oncology company developing first-in-class and novel therapies for both rare and common cancers. Our pipeline has recently expanded and now includes two clinical-stage products with common regulatory and development strategies.
Our cutting-edge scientific approach is focused on targets that are uniquely expressed within cancer cells, resulting in highly targeted new therapies. We also apply a variety of therapeutic strategies to address different medical challenges - from antibodies and antibody-drug conjugates (ADCs) to small molecules and chimeric antigen receptor T-cells (CAR-T).
By leveraging our strong scientific and development skills, as well as academic collaborations, we are working to rapidly advance our two clinical-stage pipeline products, cirmtuzumab and TK216. Both cirmtuzumab and TK216 are being developed for various tumor types, including some of the most devastating and underserved forms of cancer.

TypePrivate
Founded2013
HQSan Diego, CA, US
Websiteoncternal.com

Latest Updates

Cybersecurity ratingAMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Oncternal Therapeutics

Jim Breitmeyer

Jim Breitmeyer

President and Chief Executive Officer
Richard Vincent

Richard Vincent

Chief Financial Officer
Salim Yazji

Salim Yazji

Chief Medical Officer
Gunnar Kaufmann

Gunnar Kaufmann

Chief Scientific Officer
Rajesh Krishnan

Rajesh Krishnan

Chief Technology Officer
Pablo Urbaneja

Pablo Urbaneja

Senior Vice President Corporate Development
Show more

Oncternal Therapeutics Office Locations

Oncternal Therapeutics has an office in San Diego
San Diego, CA, US (HQ)
12230 El Camino Real #300
Show all (1)

Oncternal Therapeutics Financials and Metrics

Summary Metrics

Founding Date

2013

Oncternal Therapeutics total Funding

$18.6 m

Oncternal Therapeutics latest funding size

$18.4 m

Time since last funding

5 years ago
Oncternal Therapeutics's latest funding round in February 2017 was reported to be $18.4 m. In total, Oncternal Therapeutics has raised $18.6 m
Show all financial metrics

Oncternal Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

A

93/100

SecurityScorecard logo

Oncternal Therapeutics Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

30-39

out of 100

CSRHub logo

Oncternal Therapeutics Online and Social Media Presence

Embed Graph

Oncternal Therapeutics News and Updates

Oncternal Therapeutics Presents New Preclinical Data from its anti-ROR1 Cell Therapy Collaboration with the Karolinska Institutet at the EHA2022 Congress

SAN DIEGO, June 10, 2022 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that preclinical data from its ROR1-targeting cell therapy programs will be highlighted in a …

Oncternal Therapeutics Presents Rationale and Plans for its Registrational Phase 3 Study Evaluating Zilovertamab in Combination with Ibrutinib at the EHA 2022 Congress

SAN DIEGO, June 10, 2022 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that the rationale and plans for its upcoming Phase 3 ZILO-301 (zilovertamab plus ibrutinib t…

Oncternal Therapeutics Presents Updated Interim Data for Zilovertamab in Combination with Ibrutinib at ASCO 2022

SAN DIEGO, May 26, 2022 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced updated interim clinical data from the ongoing Phase 1/2 CIRLL (Cirmtuzumab and Ibrutinib targ…

Oncternal Therapeutics Deprioritizes Development of ONCT-216 to Focus Resources on Phase 3 Trial for Zilovertamab in the Treatment of Mantle Cell Lymphoma

SAN DIEGO, April 13, 2022 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it has deprioritized further development of ONCT-216 to reallocate resources to zilover…

Oncternal Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2021 Financial Results

SAN DIEGO, March 07, 2022 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it will report fourth quarter and full year 2021 financial results after the U.S. finan…

Oncternal Therapeutics Hosting Key Opinion Leader Webinar on Hematological Malignancies and Prostate Cancer

SAN DIEGO, Jan. 20, 2022 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it will host a key opinion leader (KOL) webinar on hematological malignancies and prosta…
Show more

Oncternal Therapeutics Frequently Asked Questions

  • When was Oncternal Therapeutics founded?

    Oncternal Therapeutics was founded in 2013.

  • Who are Oncternal Therapeutics key executives?

    Oncternal Therapeutics's key executives are Jim Breitmeyer, Richard Vincent and Salim Yazji.

  • Who are Oncternal Therapeutics competitors?

    Competitors of Oncternal Therapeutics include Scorpion Therapeutics, Aptevo Therapeutics and Enara Bio.

  • Where is Oncternal Therapeutics headquarters?

    Oncternal Therapeutics headquarters is located at 12230 El Camino Real #300, San Diego.

  • Where are Oncternal Therapeutics offices?

    Oncternal Therapeutics has an office in San Diego.

  • How many offices does Oncternal Therapeutics have?

    Oncternal Therapeutics has 1 office.